Fluorescence Imaging of Risankizumab-800CW in Inflammatory Bowel Disease

NCT06606808 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Ulcerative Colitis (UC)
Crohn Disease (CD)

Interventions

DRUG: Risankizumab-800CW 4.5 mg
DRUG: Risankizumab-800CW 15 mg
DRUG: Risankizumab-800CW 25 mg
DRUG: Risankizumab-800CW optimal dose

Sponsor

University Medical Center Groningen